Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Pharmaceutical firm Novartis AG (NYSE:NVS)'s shares are up by 44% over the past year and by 7.6% year-to-date. The tail end of 2025 saw several analysts discuss the firm. For instance, Morgan Stanley upgraded the shares to Overweight and increased the share price target to CHF110 from CHF108. The bank pointed out that Novartis AG (NYSE:NVS)'s shares had suffered excessively after the firm's third-quarter earnings, and the selloff was driven by legacy products. Consequently, the troubles with the older products had been fully reflected in the stock. TD Cowen discussed the firm in November as it reiterated a Hold rating and a $140 share price target. According to the financial firm, some of Novartis AG (NYSE:NVS)'s growth projections might be a bit too optimistic. Cramer has also discussed the firm over the past few months. According to him, while the pharmaceutical company's weight loss pill marks a key early mover advantage, medical professionals will be hesitant to advise patients t
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"PR Newswire
- Breakthrough Therapy Status For Ianalumab Could Be A Game Changer For Novartis (SWX:NOVN) [Yahoo! Finance]Yahoo! Finance
- Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25% [Yahoo! Finance]Yahoo! Finance
- Why I Am Buying the Schwab International Equity ETF (SCHF) and Never Looking Back [Yahoo! Finance]Yahoo! Finance
- Novartis (NYSE:NVS) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.MarketBeat
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- 1/16/26 - Form S-8
- NVS's page on the SEC website